biospectrumasiaSeptember 16, 2019
Tag: Novotech , South Korea , clinical trials advancements
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Asia-Pacific specialist CRO Novotech has welcomed the South Korean Comprehensive Five-year Plan for the Advancement of Clinical Trials aimed at further establishing the country as a leading research and clinical trial destination in the region and globally.
Novotech identified key points expected effective in 2019 from the Comprehensive Five-year Plan that will be of particular interest to US biotech.
Besides the changes in 2019, differentiating approval systems for multi-national phase III trials to have already obtained the nod in major would be applied in 5 years.
According to the Korea Biomedical Review the new Comprehensive Five-year Plan will involve a significant increase in expert staff to support rapid approval processes.
The Five-year Plan will focus on:
Novotech CEO Dr John Moller said:
"South Korea is already a top 10 location globally for clinical trials and the capital Seoul is the top-ranked globally." He said the new five-year plan will deliver valuable improvements that will attract even more international biotechs.
"We have a strong Novotech CRO team based in Seoul which has grown by over 25% over the past year to accommodate the increasing demand for trials in South Korea - particularly from US biotechs."
About 600 industry-sponsored trials were initiated in South Korea in the last 12 months.
In an interview with Life Science Leader, KONECT mentioned:
"With 66 hospitals per million people, South Korea ranks second among OECD (Organization of Economic Cooperation and Development) members. Rapid recruitment and startup are enabled by optimized recruitment practices and the large volumes of daily patient traffic," KONECT said.
Novotech, known as the Asia-Pacific CRO, has offices and teams through the region as well as partnerships and long-term relationships with major hospitals that directly benefit clients.
Novotech’s in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.
-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: